CBS-3595

• Description :

  CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808) -induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases[1].

• CAS Number :

  [908380-97-2]

• UNSPSC :

  12352005

• Target :

  P38 MAPK; Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cbs-3595.html

• Smiles :

  CC(NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=C(S(C)=O)N2C)=C1)=O

• Molecular Formula :

  C18H17FN4O2S

• Molecular Weight :

  372.42

• References & Citations :

  [1]Koch DA, et al. Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats. Rheumatology (Oxford) . 2014 Mar;53 (3) :425-32.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1